EKSO vs MYO

For growth investors, Myomo, Inc.

(MYO) is the stronger pick with 25. 7% revenue growth year-over-year, versus -28. 6% for Ekso Bionics Holdings, Inc. (EKSO). Analysts rate Ekso Bionics Holdings, Inc. (EKSO) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Ekso Bionics Holdings, Inc.

(EKSO) delivered a total return of -85. 5%, compared to -90. 9% for Myomo, Inc. (MYO). Over 10 years, the gap is even starker: EKSO returned -99. 3% versus MYO's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Myomo, Inc.

(MYO) is the lower-risk stock at 1. 63β versus Ekso Bionics Holdings, Inc. 's 2. 02β — meaning EKSO is approximately 24% more volatile than MYO relative to the S&P 500. On balance sheet safety, Ekso Bionics Holdings, Inc. (EKSO) carries a lower debt/equity ratio of 29% versus 170% for Myomo, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Myomo, Inc.

(MYO) is pulling ahead at 25. 7% versus -28. 6% for Ekso Bionics Holdings, Inc. (EKSO). On earnings-per-share growth, the picture is similar: Myomo, Inc. grew EPS -131. 3% year-over-year, compared to -776. 8% for Ekso Bionics Holdings, Inc.. Over a 3-year CAGR, MYO leads at 38. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Myomo, Inc.

(MYO) is the more profitable company, earning -38. 1% net margin versus -91. 4% for Ekso Bionics Holdings, Inc. — meaning it keeps -38. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MYO leads at -35. 2% versus -104. 1% for EKSO. At the gross margin level — before operating expenses — MYO leads at 65. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, EKSO (0.

8% yield) pays a dividend. MYO does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Ekso Bionics Holdings, Inc.

(EKSO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (0. 8% yield). Myomo, Inc. (MYO) carries a higher beta of 1. 63 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EKSO: -99. 3%, MYO: -99. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: EKSO is a small-cap quality compounder stock; MYO is a small-cap high-growth stock. EKSO pays a dividend while MYO does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.